Our
results support a model in which ApoC - III on TRLs contributes to
hypertriglyceridemia, primarily by preventing TRL hepatic clearance via both LDLR and LRP1.
However, far from encouraging people to consume unhealthy fats, this promising outcome may
result in new therapeutic uses of Incas» peanut for the treatment of both
hypertriglyceridemia and type 2 diabetes, as well as in new ways of preventing cardiovascular and metabolic diseases.